Bio-Rad Laboratories (BIO) 145.40 $BIO Medical Product

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bio-Rad Laboratories (BIO) 145.40 $BIO

Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 31.12 (+0.82), INSY: 18.05 (+2.85), CSII: 19.85 (+0.47), BIO: 145.40 (-0.65), CNAT: 2.39 (+0.06)

Bio-Rad to Report Second-Quarter 2016 Financial Results Wednesday, August 3, 2016
Marketwire Canada - Mon Jul 11, 1:03PM CDT
HERCULES, CA--(Marketwired - Jul 11, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) , a global provider of life science research and clinical diagnostic products, will report financial results for the second quarter 2016 on Wednesday, August 3, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) that day.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)

Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) , a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Bio-Rad Laboratories, Inc.
ACCESSWIRE - Mon May 16, 2:25PM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Levi & Korsinsky announces it has commenced an investigation of Bio-Rad Laboratories, Inc. (NYSE: BIO) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/bio-rad-laboratories or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
BIO: 145.40 (-0.65)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Bio-Rad Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE - Mon May 16, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 145.40 (-0.65)

Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported first-quarter profit of $12.3 million.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)

Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) , a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
BIO: 145.40 (-0.65), ILMN: 165.42 (-1.50), BIO.B: 146.00 (-1.50)

Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)

Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) , a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)

Fluidigm's Q4 Preliminary Results Fail to Woo Investors
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 12:40PM CST
Market is not really upbeat about Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter of 2015.
FLDM: 10.44 (+0.07), BIO: 145.40 (-0.65), ILMN: 165.42 (-1.50), EXAC: 27.12 (-0.14)

Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) , a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety.
IBM: 159.93 (-0.65), BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)

Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics
BusinessWire - Mon Jan 11, 1:31PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and Illumina, Inc. (NASDAQ: ILMN) today announced an exclusive partnership to develop the most comprehensive next-generation sequencing (NGS) workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly and time-consuming process.
BIO: 145.40 (-0.65), ILMN: 165.42 (-1.50)

Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) , a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)

Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) , a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.
BIO: 145.40 (-0.65), BIO.B: 146.00 (-1.50)

FDA Okays Bio-Rad D-100 for HbA1c (Diabetes) Testing
Zacks Equity Research - Zacks Investment Research - Mon Dec 21, 1:25PM CST
Bio-Rad's (BIO) D-100 System delivers rapid high-quality HbA1c testing, without sacrificing the ability to detect hemoglobin variants that can interfere with the interpretation of test results.
CAPR: 3.79 (+0.04), ICUI: 115.70 (-0.32), INSY: 18.05 (+2.85), BIO: 145.40 (-0.65)

10X Genomics Founders Prevail in Dispute with Bio-Rad
BusinessWire - Mon Dec 21, 6:00AM CST
10X Genomics, Inc., today announced that its founders and executive officers, Drs. Serge Saxonov, Benjamin Hindson and Kevin Ness, have unequivocally prevailed in an arbitrated dispute brought against them by Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 145.40 (-0.65)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading

Top 5 Most Recently Viewed Articles

Neurotrope, Inc. Achieves New Milestone with Stock Surge

Updated Category News Views 147

Neurotrope, Inc. Reaches New Stock Milestone Neurotrope, Inc. (NASDAQ: NTRP) has recently achieved a significant milestone in the stock market, soaring to a 52-week high with its price reaching $7.00. This impressive climb indicates a remarkable 124.95% increase over the past year, showcasing strong investor interest and confidence in the company's future prospects. The...

Continue Reading
Lil Nas X's Legal Challenges and Public Struggles Unfold

Updated Category News Views 284

Lil Nas X Pleads Not Guilty to Serious Charges Grammy-winning musician Lil Nas X has recently made headlines for pleading not guilty to multiple felony charges stemming from an incident involving police officers. This situation arose when he was found walking unclothed on the streets of Los Angeles. Understanding the Legal Battle Ahead The rapper, known legally as Montero...

Continue Reading
Exyte's Strategic Acquisition of TTP Group Enhanced Operations

Updated Category News Views 51

Exyte Acquires TTP Group to Strengthen Engineering Expertise Exyte, a leader in high-tech facility engineering, has officially completed the acquisition of TTP Group, enhancing its operations and expertise especially in the biopharma and life sciences sectors. This acquisition marks a significant milestone for Exyte as it melds TTP's capabilities with its own, aiming to...

Continue Reading
Unveiling Health Innovations: Zepp Health at CES 2024 Events

Updated Category News Views 372

Zepp Health Showcases Innovative Technologies at CES Zepp Health Corporation (NYSE: ZEPP), a leader in health technology and smart wearables, is excited to announce its participation in significant media events like Pepcom and ShowStoppers at CES. These occasions will showcase Zepp Health's latest advancements in smart wearables and health technologies, aimed at...

Continue Reading
Meridian Locks $186M Loan for NJ Condo Project

Updated Category News Views 163

New Jersey's Coastline Gets a $186 Million Facelift Here's a move that'll shake the Jersey Shore awake: Meridian Capital Group's just put their money where the sand is with a massive $186 million scoop for a new high-end condominium project in Asbury Park. You couldn't make up a better setting—a beachfront spot ripe for some high-end living. But let's not get too...

Continue Reading